Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q3 2018 · 10-Q
Revenue$1.12M$1.12M+63.5% vs Q3 2017 Net Income-$32.74M-$32.74MN/M vs Q3 2017 EPS Diluted-$1.06-$1.06N/M vs Q3 2017 Gross Profit$435,000+88.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
Operating Cash Flowderived-$29,858,000N/M Free Cash Flowderived-$30,418,000N/M Margins · derivedGross margin38.9%+5.1 pt vs Q3 2017
Operating margin-1908.9%+833.2 pt vs Q3 2017
Net margin-2928.4%−268.8 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 6, 2018 · 37 d after period end